|
|
|
|
|
Nevirapine
drug data and news
Nevirapine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Generic name | Nevirapine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Brand Names/Synonyms | BIRG 0587; DRG-0116; HSDB 7164; NEV; NVP; Nevirapine; Nevirapine [Usan:Inn]; Viramune | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Indication | For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsored links | Description | Not Available | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacology | Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mechanism Of Action | Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Nevirapine News (When available) |
Tercica to Present at Ninth Annual Lehman Brothers' Global Health ... 07 Mar 2006 Insmed Incorporated Announces Proposed Public Offering of Common ... 07 Mar 2006 Apidra (insulin glulisine [rDNA origin] injection) Now Available ... Feb 28, 2006 God and the New Foodstuffs Mar 1, 2006 Apidra(R) - a New Rapid-Acting Insulin Analog - Is Now Available ... Feb 28, 2006 Apidra - a New Rapid-Acting Insulin Analog - Is Now Available in ... Feb 28, 2006 Apidra(R) - a New Rapid-Acting Insulin Analog - Is Now Available ... Feb 28, 2006 Sanofi's Apidra hits the US market Mar 2, 2006 FDA Approves Inhalable Insulin Mar 3, 2006 First report of a defect of processing potatoes in Texas and ... Feb 27, 2006 Lilly launches new diabetes product Feb 8, 2006 Lilly Launches Humalog® Mix50/50™ Insulin In United States Feb 12, 2006 FDA Approves First Ever Inhaled Insulin Combination Product for ... Feb 15, 2006 Lilly Launches Humalog Mix50/50 Insulin in United States Feb 7, 2006 NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating ... Feb 16, 2006 CHMP Recommends Authorization to Market Preotact (PREOS) in Europe Feb 23, 2006 Tercica Reports Fourth Quarter Financial Results; Conference Call ... Feb 15, 2006 CHMP Recommends Authorization to Market Preotact(R) (PREOS(R)) in ... Feb 23, 2006 NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating ... Feb 16, 2006 Former Professor Sued For Patent Infringement Feb 9, 2006 NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating ... Feb 16, 2006 Former Professor Sued For Patent Infringement 09 Feb 2006 MultiVu Video Feed: FDA Approves Exubera(R) (insulin human [rDNA ... Jan 27, 2006 Lilly launches new diabetes product Feb 8, 2006 Roger DuBuis SA, Helvetia dispute ending US distribution contract Jan 17, 2006 Reader's Digest Association Announces 2Q Fiscal 2006 Earnings ... Jan 26, 2006 Reader's Digest Association Announces 2Q Fiscal 2006 Earnings ... Jan 26, 2006 FDA Approves First Ever Inhaled Insulin Combination Product for ... Jan 27, 2006 Now it's true: Pfizer's Exubera approved Jan 27, 2006 Exubera Inhaled Insulin Expected to be Available Soon for Diabetes ... Jan 28, 2006 Pfizer Receives FDA Approval for Exubera, the First Inhalable Form ... Jan 27, 2006 Inhaled Insulin Approved by FDA Jan 27, 2006 FDA Approves Exubera, First Inhalable Form Of Insulin For ... Jan 29, 2006 Pfizer Receives FDA Approval for Exubera, the First Inhalable Form ... Jan 27, 2006 Alkermes and Lilly Announce Agreement for the Development and ... Jan 10, 2006 Pfizer Receives FDA Approval for Exubera, the First Inhaleable ... Jan 27, 2006 Innovative Hand-Held Insulin Device Effectively Controls Diabetes ... Jan 27, 2006 Inhaled Human Insulin Approved for Diabetes Treatment Jan 27, 2006 Senior Diabetics Say Goodbye to Injections as FDA Welcomes Exubera Jan 28, 2006 Pfizer Receives FDA Approval for Exubera, the First Inhaleable ... Jan 28, 2006 Pfizer Receives FDA Approval for Exubera, The First Inhalable Form Jan 31, 2006 Tercica to Hold 2005 Fourth Quarter and Year End Financial Results ... Feb 1, 2006 Pfizer Receives FDA Approval for Exubera, the First Inhaleable ... Jan 27, 2006 Pfizer Receives FDA Approval for Exubera and CytoDyn Annual ... Jan 30, 2006 Novo Nordisk Introduces New Storage Flexibility For Norditropin® ... Jan 29, 2006 FDA APPROVES Exubera(R) Jan 31, 2006 Alkermes and Lilly Announce Agreement for the Development and ... Jan 9, 2006 Novo Nordisk Introduces New Storage Flexibility for Norditropin(R) Jan 11, 2006 Novo Nordisk Introduces New Storage Flexibility for Norditropin Jan 11, 2006 Novo Nordisk Introduces New Storage Flexibility for Norditropin Jan 11, 2006 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dosage Forms | Tablets, Oral suspension | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug_Category | Anti-HIV Agents; Nonnucleoside Reverse Transcriptase Inhibitors; ATC:J05AG01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Absorption | 90% (absolute bioavailability 93 ± 9%) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interactions |
-->Interactions for Nevirapine: Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A4 and 2B6. Nevirapine is known to be an inducer of these enzymes. As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when coadministered with nevirapine. The specific pharmacokinetic changes that occur with co-administration of nevirapine and other drugs are listed in CLINICAL PHARMACOLOGY, Table 1. Clinical comments about possible dosage modifications based on these pharmacokinetic changes are listed in Table 3. The data inTables 1 and 3 are based on the results of drug interaction studies conducted in HIV-1 seropositive subjects unless otherwise indicated. In addition to established drug interactions, there may be potential pharmacokinetic interactions between nevirapine and other drug classes that are metabolized by the cytochrome P450 system. These potential drug interactions are listed in Table 4. Although specific drug interaction studies in HIV-1 seropositive subjects have not been conducted for the classes of drugs listed in Table 4, additional clinical monitoring may be warranted when co-administering these drugs. The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex. As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time. When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.
aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.
Fat redistribution: Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Toxicity | Symptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Organisms Affected | Human immunodeficiency virus | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical IUPAC Name | 1-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido [3,2-b:2',3'-e][1,4] diazepin-6-one | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical Formula | C15H14N4O | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Weight | 266.298 g/mol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Smiles String | CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Melting Point | 196.06 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Water Solubility | 0.7046 mg/L | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| State | Solid (white to off-white crystalline powder) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LogP/Hphobicity | 1.725 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Isoelectric Point | Not Available | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Biotransformation | Hepatic. In vivo studies in humans and in vitro studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 3A4 metabolism to several hydroxylated metabolites. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Half Life | 45 hours | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Protein Binding [%] | 60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RxList Link | RXlist | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsored links | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Reference |
http://www.drugs.com/cons/Nevirapine.html http://www.rxlist.com/cgi/generic2/nevira.htm | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Type | Approved Drug | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accession No | APRD00705 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CAS Registry Number | 129618-40-2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| KEGG Compound ID | C07263 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PubChem ID | SID:197039 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PharmGKB ID | PA450616 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SwissProt ID | Not Available | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GenBank ID | Not Available | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug ID Number [DIN] | 2238748 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |